ARCHIVES

Vaccine Increases PFS by 4 Months In Phase II Per-Protocol Analysis

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Commissioner Holds Up IND While Reviewing Toxicology Guidelines

August 14, 1981

Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine

August 31, 2012

Group trials need prioritization, review, NCI official says.

July 25, 2003

LabCorp Marketing Of Ovarian Cancer Test Unlawful, FDA Says In Warning Letter.

October 17, 2008

In Brief: Lou Carrese, NCI Associate Director, Dies; Myers, Ransahoff Head Two New Organ Systems Group

May 9, 1986

Klausner To Serve As Advisor On Bioterrorism For NAS.

January 4, 2002